Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study

Cancers

卷:13

Taizo Yamaguchi¹  Kazunori Noguchi²  Hideya Suga³  Masatoshi Tanaka⁴  Shusuke Okamura⁵  Masahito Nakano⁵  Tomotake Shirono⁵  Shigeo Shimose⁵  Naoki Kamachi⁵  Hideki Iwamoto⁵  Takuji Torimura⁵  Takumi Kawaguchi⁵  Hironori Koga⁵  Yu Noda⁵  Ryoko Kuromatsu⁵  Takashi Niizeki⁵ 

[1] Department of Gastroenterology and Hepatology, Iwamoto Internal Medical Clinic, Kitakyusyu 802-0832, Japan;

[2] Department of Gastroenterology and Hepatology, Omuta City Hospital, Fukuoka 836-8567, Japan;

[3] Department of Gastroenterology and Hepatology, Yanagawa Hospital, Fukuoka 832-0077, Japan;

[4] Department of Gastroenterology and Hepatology, Yokokura Hospital, Miyama, Fukuoka, 839-0295, Japan;

[5] Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan;

关键词: lenvatinib;    alternating therapy;    intermediate stage;    TACE;    HAIC;   

DOI  :  10.3390/cancers13010160

来源: DOAJ

【 摘 要 】

We aimed to evaluate the impact of alternating lenvatinib (LEN) and trans-arterial therapy (AT) in patients with intermediate-stage hepatocellular carcinoma (HCC) after propensity score matching (PSM). This retrospective study enrolled 113 patients with intermediate-stage HCC treated LEN. Patients were classified into the AT (n = 41) or non-AT group (n = 72) according to the post LEN treatment. Overall survival (OS) was calculated using the Kaplan–Meier method and analyzed using a log-rank test after PSM. Factors associated with AT were evaluated using a decision tree analysis. After PSM, there were no significant differences in age, sex, etiology, or albumin-bilirubin (ALBI) score/grade between groups. The survival rate of the AT group was significantly higher than that of the non-AT group (median survival time; not reached vs. 16.3 months, P = 0.01). Independent factors associated with OS were AT and ALBI grade 1 in the Cox regression analysis. In the decision tree analysis, age and ALBI were the first and second splitting variables for AT. In this study, we show that AT may improve prognosis in patients with intermediate-stage HCC. Moreover, alternating LEN and trans-arterial therapy may be recommended for patients below 70 years of age with ALBI grade 1.

【 授权许可】

Unknown